When Alistair Irvine first started raising money for a University of Bristol spinout named Scarlet Therapeutics about two years ago, he got one question a lot: How was Scarlet, which is looking to turn red blood cells into therapies, going to compete with Rubius Therapeutics? Things are looking different as…
...